Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or ...

It has not been established whether atacicept slows kidney function decline long-term, how ...

High blood pressure can speed up kidney damage. Here’s how managing blood pressure with IgA nephropathy protects your filters ...

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), ...

Data from the first stage of a phase 3 study show significant reductions in proteinuria among patients treated with telitacicept.

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A ...

The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune ...

IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...

ORIGIN 3 randomized 431 biopsy‑confirmed IgAN patients 1:1; atacicept 150 mg weekly SC produced the largest placebo‑adjusted UPCR reduction reported at week 36. Accelerated approval hinged on ...

Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...

Learn why Oxford scores predict IgA nephropathy outcomes, and how supportive drugs plus low-salt lifestyle protect remaining nephrons. How does targeted-release budesonide different from systemic ...